Investigators Aim at B-Cell Malignancies Using Targeted Radiopharmaceutical

Rachel Narozniak
Published: Tuesday, Oct 15, 2019
Laura Finn, MD, principal investigator, CLOVER, Genitourinary Medical Oncology, Seattle Cancer Care Alliance

Laura Finn, MD

In the phase II CLOVER-1 trial (NCT02952508), investigators are evaluating whether CLR 131, a first-in-class radioiodinated phospholipid drug conjugate that selectively delivers radiation to malignant cells, will be an effective option for patients with difficult-to-treat relapsed or refractory (R/R) B-cell lymphomas. Results have so far been presented from the multiple myeloma (MM) and diffuse large B-cell lymphoma (DLBCL) cohorts.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x